• Ziqiong Wang, Haiyan Ruan, Liying Li, Xin Wei, Ye Zhu, Jiafu Wei, Xiaoping Chen, and Sen He.
• Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China.
• Ups. J. Med. Sci. 2021 Jan 1; 126.

BackgroundThis study investigates the predictive value of the systemic immune-inflammation index (SII), which was calculated as platelet × neutrophil/lymphocyte ratio, for all-cause mortality in patients with hypertrophic cardiomyopathy (HCM).MethodsA total of 360 HCM patients were enrolled. They were divided into three groups based on the tertiles of baseline SII. The association between SII and all-cause mortality was analyzed.ResultsThere were 53 HCM patients who died during a mean follow-up time of 4.8 years (min: 6 days and max: 10.8 years), and the mortality rate was 3.0 per 100 person years. The cumulative mortality rate was significantly different among the three tertiles of SII (P = 0.004), and the mortality rate in tertile 3 was much higher than that in the first two tertiles. In reference to tertile 1, the fully adjusted hazard ratios of all-cause mortality were 1.02 for the tertile 2 (95% confidence interval [CI]: 0.45-2.31, P = 0.966) and 2.31 for tertile 3 (95% CI: 1.10-4.87, P = 0.027). No significant interactions between SII and other variables were observed during subgroup analysis. The discriminative power was better for mid-term outcome than that for short-term or long-term outcomes. Sensitivity analyses including patients with normal platelet and white blood cell count have revealed similar results.ConclusionSII was a significant risk factor for all-cause mortality in HCM patients. However, the discriminative power was poor to moderate. It could be used in combination with other risk factors in mortality risk stratification in HCM.© 2021 The Author(s). Published by Upsala Medical Society.

13 keywords...

hide…